On Tuesday, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was -5.54% drop from the session before settling in for the closing price of $68.45. A 52-week range for ARWR has been $9.57 – $72.36.
Annual sales at Healthcare sector company grew by 57.10% over the past five years. When this article was written, the company’s average yearly earnings per share was at -31726.54%. With a float of $125.82 million, this company’s outstanding shares have now reached $135.70 million.
Arrowhead Pharmaceuticals Inc (ARWR) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arrowhead Pharmaceuticals Inc stocks. The insider ownership of Arrowhead Pharmaceuticals Inc is 7.35%, while institutional ownership is 81.10%. The most recent insider transaction that took place on Dec 16 ’25, was worth 3,398,142. Before that another transaction happened on Dec 15 ’25, when Company’s Chief Executive Officer sold 130,000 for $68.85, making the entire transaction worth $8,950,615. This insider now owns 3,971,255 shares in total.
Arrowhead Pharmaceuticals Inc (ARWR) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -1.39 earnings per share (EPS) during the time that was less than consensus figure (set at -0.72) by -0.67. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -31726.54% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
You can see what Arrowhead Pharmaceuticals Inc (ARWR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.86. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.59. Likewise, its price to free cash flow for the trailing twelve months is 55.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.07, a number that is poised to hit 0.12 in the next quarter and is forecasted to reach -4.22 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) saw its 5-day average volume 2.87 million, a positive change from its year-to-date volume of 2.16 million. As of the previous 9 days, the stock’s Stochastic %D was 65.98%.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 86.57%, which indicates a significant increase from 71.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 5.36 in the past 14 days, which was higher than the 2.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $46.23, while its 200-day Moving Average is $25.29. Nevertheless, the first resistance level for the watch stands at $68.70 in the near term. At $72.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $77.34. If the price goes on to break the first support level at $60.06, it is likely to go to the next support level at $55.47. The third support level lies at $51.42 if the price breaches the second support level.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
There are 135,880K outstanding shares of the company, which has a market capitalization of 8.78 billion. As of now, sales total 829,450 K while income totals -1,630 K. Its latest quarter income was 256,470 K while its last quarter net income were -23,750 K.
